0001415889-23-016539.txt : 20231215
0001415889-23-016539.hdr.sgml : 20231215
20231215180007
ACCESSION NUMBER: 0001415889-23-016539
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231213
FILED AS OF DATE: 20231215
DATE AS OF CHANGE: 20231215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gillies Hunter
CENTRAL INDEX KEY: 0001868997
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 231491660
MAIL ADDRESS:
STREET 1: C/O AEROVATE THERAPEUTICS, INC.
STREET 2: 200 BERKELEY STREET, FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4-12152023_061201.xml
X0508
4
2023-12-13
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001868997
Gillies Hunter
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM
MA
02451
false
true
false
false
CHIEF MEDICAL OFFICER
1
Common Stock
2023-12-13
4
M
0
2103
1.74
A
5354
D
Common Stock
2023-12-13
4
S
0
2103
19.50
D
3251
D
Common Stock
2023-12-14
4
M
0
9897
1.74
A
13148
D
Common Stock
2023-12-14
4
S
0
9897
19.50
D
3251
D
Stock Option (Right to Buy)
1.74
2023-12-13
4
M
0
653
0
D
2030-09-03
Common Stock
653
15444
D
Stock Option (Right to Buy)
1.74
2023-12-13
4
M
0
1450
0
D
2030-09-03
Common Stock
1450
17503
D
Stock Option (Right to Buy)
1.74
2023-12-14
4
M
0
2700
0
D
2030-09-03
Common Stock
2700
12744
D
Stock Option (Right to Buy)
1.74
2023-12-14
4
M
0
7197
0
D
2030-09-03
Common Stock
7197
10306
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
/s/ George A. Eldridge, Attorney-in-Fact
2023-12-15